US · LIMN
Liminatus Pharma, Inc. Class A Common Stock
- Sector
- Healthcare · Biotechnology
- Headquarters
- La Palma, CA 90623
- Website
- liminatuspharma.com
Price · as of 2024-12-31
$0.21
Market cap 7.86M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
AI valuation
Our deep-learning model estimates Liminatus Pharma, Inc. Class A Common Stock's (LIMN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.21
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LIMN | Liminatus Pharma, Inc. Cl… | $0.21 | 7.86M | — | — | — | — | — | — | — | — | — | — | 0.00% | — | — | 21.87% | 87.68% | -79.23% | -0.32 | -21.04 | 0.09 | 0.09 | -1.57 | 16667.00% | — | -713.00% | — | -0.36 | 93.72% | — | 0.00% | — | — | — | — | — |
| ATHE | Alterity Therapeutics Lim… | $3.44 | 58.29M | +500% | +3% | — | — | -6.79 | 1.95 | 15.18 | -2.87 | — | 1.95 | 97.66% | -267.96% | -223.35% | -43.23% | -905.76% | -37.23% | 0.00 | — | 12.98 | 12.62 | 2.26 | -6346.00% | 3532.00% | -920.00% | -13.87% | -3.24 | -711.67% | 0.00% | 0.00% | 24.86% | -2.88 | -3.67 | 7.73 | 6.97 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| DYAI | Dyadic International, Inc… | $0.78 | 28.19M | +4,253% | -26% | — | — | -7.32 | 17.21 | 12.16 | -7.12 | — | 17.21 | 65.82% | -168.82% | -166.19% | -139.16% | 396.74% | -64.01% | 2.05 | -13.79 | 4.01 | 3.88 | 0.27 | -1667.00% | 2058.00% | -4091.00% | -9.35% | -1.62 | 267.25% | 0.00% | 0.00% | 0.00% | -6.49 | -9.64 | 10.96 | -9.43 |
| EVAX | Evaxion Biotech A/S | $3.16 | 19.96M | +25,906% | -76% | — | — | -0.19 | -1.22 | 0.60 | -0.72 | — | -1.22 | 100.00% | -440.55% | -316.00% | 331.20% | -693.28% | -83.29% | -6.11 | -15.31 | 2.01 | 1.58 | -0.52 | -6975.00% | 448082.00% | -2721.00% | -641.54% | -2.96 | -654.36% | 0.00% | 0.00% | 11.80% | -0.48 | -0.55 | 2.11 | -16.41 |
| GBIO | Generation Bio Co. | $5.34 | 35.98M | +46% | -60% | — | — | -0.27 | 0.41 | 1.78 | 0.76 | -40.69 | 0.41 | 100.00% | -715.82% | -661.91% | -91.02% | -912.79% | -43.46% | 1.09 | — | 5.50 | 5.33 | -0.23 | 66.00% | 23692.00% | 5125.00% | -256.40% | -2.53 | -583.12% | 0.00% | 0.00% | 39.99% | 0.39 | 0.62 | -2.82 | -5.24 |
| JSPR | Jasper Therapeutics, Inc. | $1.38 | 22.43M | — | — | — | — | -1.10 | 1.27 | — | -0.11 | — | 1.27 | 0.00% | — | — | -101.73% | 1104.03% | -81.55% | 0.03 | — | 4.98 | 4.70 | 0.93 | -2087.00% | — | 2067.00% | -80.64% | -4.11 | 914.55% | 0.00% | 0.00% | 0.00% | -0.11 | -0.13 | — | -3.88 |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| SABS | SAB Biotherapeutics, Inc. | $4.10 | 39.19M | +213% | -84% | — | +2,692% | -0.44 | 0.58 | 11.35 | 0.04 | — | 0.58 | -262.41% | -3244.87% | -2579.03% | -81.92% | -519.55% | -53.23% | 0.18 | -134.77 | 2.98 | 2.61 | 0.15 | -5183.00% | -4094.00% | 3679.00% | -230.79% | -4.30 | -419.29% | 0.00% | 0.00% | 0.00% | 0.03 | 0.03 | -0.82 | -6.18 |
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
- CEO
- Chris Kim
- Employees
- 3
- Beta
- 0.41
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.21) − 1 = — (DCF, example).